Immunocore (IMCR) vs Ultragenyx Pharmaceutical (RARE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Immunocore (IMCR) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, losing 12.9% versus a loss of 51.1%. Over five years, IMCR leads with a -22.7% price change compared with -80.7% for RARE. Ultragenyx Pharmaceutical is the larger company by market cap ($1.53 billion vs $1.51 billion), about 1.0 times the size, while Immunocore is growing revenue faster (+29.0% vs +20.2%).
Immunocore converts more of its revenue into profit, with a net margin of -8.9% versus -85.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMCR | RARE |
|---|---|---|
| Share price | $29.39 | $15.48 |
| Market cap | $1.51B | $1.53B |
| 1-day change | +1.03% | +1.24% |
| YTD return | -15.33% | -32.70% |
| 1-year return | -12.94% | -51.11% |
| 5-year return | -22.66% | -80.65% |
| Forward P/E | — | 22.87 |
| EPS (TTM) | $-0.36 | $-5.82 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $400.02M | $673.00M |
| Revenue growth (YoY) | +28.95% | +20.18% |
| Net income (latest FY) | $-35.51M | $-575.00M |
| Gross margin | 98.73% | — |
| Operating margin | -11.34% | -79.49% |
| Net margin | -8.88% | -85.44% |
| 52-week high | $40.72 | $39.89 |
| 52-week low | $27.56 | $12.73 |
| Distance from 52-week high | -27.82% | -61.19% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +113.44% | +73.06% |
| Average volume | 444.13K | 3.89M |
| Shares outstanding | 51.50M | 98.59M |
| Employees | 524 | 1,371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMCR has outperformed RARE by 38.2 percentage points over the past year.
- Immunocore is more profitable, keeping -8.9 cents of every revenue dollar as net income versus -85.4 cents for Ultragenyx Pharmaceutical.
- Immunocore grew revenue faster in its latest fiscal year (+28.95% vs +20.18%).
About Immunocore
IMCR stock →Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 524 employees
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
IMCR vs RARE FAQ
Which is bigger, Immunocore or Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.53B compared with $1.51B for Immunocore (IMCR).
Which stock has performed better over the past year, IMCR or RARE?
IMCR returned -12.94% over the past 12 months, compared with -51.11% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Immunocore and Ultragenyx Pharmaceutical in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Immunocore and Biotechnology: Pharmaceutical Preparations for Ultragenyx Pharmaceutical.